Cargando…

Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients

Acute myeloid leukemia (AML) is a heterogeneous disease with different clinical course and prognosis. microRNA-29 (miR-29) family of non-coding small RNAs can play an important role in pathogenesis of AML, but also can influence response to therapy. The purpose of the study was to evaluate miR-29c e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butrym, Aleksandra, Rybka, Justyna, Baczyńska, Dagmara, Poręba, Rafał, Kuliczkowski, Kazimierz, Mazur, Grzegorz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058678/ https://www.ncbi.nlm.nih.gov/pubmed/26862847 http://dx.doi.org/10.18632/oncotarget.7172

Ejemplares similares

Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia
por: Butrym, Aleksandra, et al.
Publicado: (2016)

Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Azacitidine in outpatient treatment – single center experience
por: Rybka, Justyna, et al.
Publicado: (2016)

The expression of Toll-like receptors and development of severe sepsis in patients with acute myeloid leukemias after induction chemotherapy
por: Rybka, Justyna, et al.
Publicado: (2014)

The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia
por: Rybka, Justyna, et al.
Publicado: (2017)

High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients
por: Butrym, Aleksandra, et al.
Publicado: (2013)

Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia
por: Butrym, Aleksandra, et al.
Publicado: (2018)

Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines
por: Kutyna, Monika M., et al.
Publicado: (2023)

Endothelial Function in Patients with Hematologic Malignancies Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation
por: Poręba, Małgorzata, et al.
Publicado: (2015)

Decreased Expression of CXCR4 Chemokine Receptor in Bone Marrow after Chemotherapy in Patients with Non-Hodgkin Lymphomas Is a Good Prognostic Factor
por: Mazur, Grzegorz, et al.
Publicado: (2014)

IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia
por: Wróbel, Tomasz, et al.
Publicado: (2014)

Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies
por: Poręba, Małgorzata, et al.
Publicado: (2018)

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
por: Butrym, Aleksandra, et al.
Publicado: (2017)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells
por: Zaidi, Sayyed K., et al.
Publicado: (2017)

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
por: Adès, Lionel, et al.
Publicado: (2022)

Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia
por: Xu, Ling, et al.
Publicado: (2014)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
por: Kara, Asude, et al.
Publicado: (2017)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia
por: Ngankeu, Apollinaire, et al.
Publicado: (2017)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Azacitidine-Induced Pneumonitis in a Patient With Acute Myeloid Leukemia and Hyperleukocytosis
por: Litvin, Rafaella, et al.
Publicado: (2022)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research
por: Skopek, Rafał, et al.
Publicado: (2023)

Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy
por: Liang, Guanghao, et al.
Publicado: (2023)

VEGF and bFGF gene polymorphisms in Polish patients with B-CLL
por: Wróbel, Tomasz, et al.
Publicado: (2013)

VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkin's Lymphoma
por: Wróbel, Tomasz, et al.
Publicado: (2013)

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
por: Ravandi, Farhad, et al.
Publicado: (2021)

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

TERT genetic variability and telomere length as factors affecting survival and risk in acute myeloid leukaemia
por: Dratwa, Marta, et al.
Publicado: (2021)

microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia
por: Han, Yoon-Chi, et al.
Publicado: (2010)

Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine
por: Tang, Li-juan, et al.
Publicado: (2019)

Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2013)

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2018)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cc3qtf76ugp4jf44td1ptsq3us